- Email: [email protected]
Recent Development of Treatment Strategy for Early Breast Cancer
Annals of Oncology 30 (Supplement 6): vi60, 2019 doi:10.1093/annonc/mdz366
EDUCATIONAL LECTURE 22 : RECENT DEVELOPMENT OF TREATMENT STRATEGY FOR EARLY BREAST CANCER EL22
Recent Development of Treatment Strategy for Early Breast Cancer
Shigehira Saji Fukushima Medical University, Dept of Medical Oncology
C The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. V
All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_6/mdz366/5582926 by guest on 24 October 2019
Strategy of peri-operative chemotherapy for early breast cancer has been changed dramatically during these 10 years. Development of high efficacy regimen with strong cellkilling drugs for reducing the recurrence risk was first priority in our research in the beginning (escalation). After that, selection of proper strength regimen adapting to
recurrence risk expectation of each patient was coming to the main stream (de-escalation). As a most recent topic, response guide treatment with neo-adjuvant therapy contributes dramatically for drug development, in which patients with non-pathological response to initial therapy thought to be a proper candidate for additional adjuvant therapy with investigation new drug. In this lecture I would like to summarize the recent changes of treatment strategy for early breast cancer.
EDUCATIONAL LECTURE 22 : RECENT DEVELOPMENT OF TREATMENT STRATEGY FOR EARLY BREAST CANCER EL22
Recent Development of Treatment Strategy for Early Breast Cancer
Shigehira Saji Fukushima Medical University, Dept of Medical Oncology
C The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. V
All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_6/mdz366/5582926 by guest on 24 October 2019
Strategy of peri-operative chemotherapy for early breast cancer has been changed dramatically during these 10 years. Development of high efficacy regimen with strong cellkilling drugs for reducing the recurrence risk was first priority in our research in the beginning (escalation). After that, selection of proper strength regimen adapting to
recurrence risk expectation of each patient was coming to the main stream (de-escalation). As a most recent topic, response guide treatment with neo-adjuvant therapy contributes dramatically for drug development, in which patients with non-pathological response to initial therapy thought to be a proper candidate for additional adjuvant therapy with investigation new drug. In this lecture I would like to summarize the recent changes of treatment strategy for early breast cancer.